Pregled bibliografske jedinice broj: 549604
Changes in body weight during pharmacological treatment of depression
Changes in body weight during pharmacological treatment of depression // International journal of neuropsychopharmacology, 14 (2011), 3; 367-375 doi:10.1017/S1461145710000933 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 549604 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Changes in body weight during pharmacological treatment of depression
Autori
Uher, R ; ... ; Henigsberg, Neven ; ... ; Farmer, A,
Izvornik
International journal of neuropsychopharmacology (1461-1457) 14
(2011), 3;
367-375
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
antidepressants; adverse effects; body weight; major depressive disorder
Sažetak
The risk of weight gain is an important determinant of the acceptability and tolerability of antidepressant medication. To compare changes in body weight during treatment with different antidepressants, body weight and height were measured at baseline and after 6, 8, 12 and 26 wk treatment with escitalopram or nortriptyline in 630 adults with moderate-to-severe unipolar depression participating in GENDEP, a part-randomized open-label study. Weight increased significantly more during treatment with nortriptyline compared to escitalopram. The weight gain commenced during the first 6 wk of nortriptyline treatment, reached on average 1.2 kg at 12 wk (0.44-point BMI increase), and continued throughout the 6-month follow-up period. Participants who were underweight at baseline gained most weight. Participants who were obese at baseline did not gain more weight during treatment. Weight gain occurred irrespective of whether weight loss was a symptom of current depressive episode and was identified as an undesired effect of the antidepressant by most participants who gained weight. There was little weight change during treatment with escitalopram, with an average increase of 0.14 kg (0.05-point BMI increase) over 12 wk of treatment. In conclusion, treatment with the tricyclic antidepressant nortriptyline was associated with moderate weight gain, which cannot be explained as a reversal of symptomatic weight loss and is usually perceived as an undesired adverse effect. While treatment with nortriptyline may be recommended in underweight subjects with typical neurovegetative symptoms, escitalopram is a suitable alternative for subjects at risk of weight gain.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081870-1880 - 1H-MRS promjene u predviđanju terapijskog odgovora, relapsa i povrata depresije (Henigsberg, Neven, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Neven Henigsberg
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE